

S4 Table. Clinical and histopathologic characteristics by histologic subtype of ADC and SqCC

Characteristic	No.	ADC (n=64)	SqCC (n=38)	p-value ^{a)}
Age (yr)	102	59 (53-67)	62 (56-68)	0.110
Sex	102			< 0.001
Male		43 (67.2)	38 (100)	
Female		21 (32.8)	0	
Smoking status	102			< 0.001
0		24 (37.5)	1 (2.6)	
1		25 (39.1)	18 (47.5)	
2		15 (23.4)	19 (50.0)	
cStage	102			0.387
II		3 (4.7)	4 (10.5)	
III		46 (71.9)	28 (73.7)	
IV		15 (23.4)	6 (15.8)	
ypStage	102			0.017
0		2 (3.1)	3 (7.9)	
I		5 (7.8)	6 (15.8)	
II		6 (9.4)	10 (26.3)	
III		38 (59.4)	17 (44.7)	
IV		13 (20.3)	2 (5.3)	
Tumor size reduction ^{b)}	80			0.003
< 30%		46 (80.7)	11 (47.8)	
≥ 30%		11 (19.3)	12 (52.2)	
Nodal downstaging	102			0.001
Absent		53 (82.8)	20 (52.6)	
Present		11 (17.2)	18 (47.4)	
Resection type	102			0.082
Lobectomy		52 (81.2)	25 (65.8)	
Bilobectomy		6 (9.4)	3 (7.9)	
Pneumonectomy		6 (9.4)	10 (26.3)	
R class	102			0.145
0		61 (95.3)	33 (86.8)	
1/2		3 (4.7)	5 (13.2)	
Neoadjuvant therapy type	102			0.527
CCRT		9 (14.1)	3 (7.9)	
Chemotherapy only		55 (85.9)	35 (92.1)	
Neoadjuvant regimen ^{c)}	96			0.216
Gemcitabine/Platinum		47 (79.7)	28 (75.7)	
Paclitaxel/Platinum		7 (11.9)	8 (21.6)	
Pemetrexed/Platinum		4 (6.8)	0	
Others		1 (1.7)	1 (2.7)	
Neoadjuvant cycle	98	3 (2-3)	2 (2-3)	0.151
Adjuvant therapy	102			0.172
No		14 (21.9)	13 (34.2)	
Yes		50 (78.1)	25 (65.8)	
Pleural invasion	102			< 0.001
Absent		31 (48.4)	31 (81.6)	
Present		33 (51.6)	7 (18.4)	
Lymphovascular invasion	102			0.057
Absent		14 (21.9)	15 (39.5)	
Present		50 (78.1)	23 (60.5)	
Perineural invasion	102			0.360
Absent		55 (85.9)	30 (78.9)	
Present		9 (14.1)	8 (21.1)	

STAS^{d)}	102			0.013
Absent		29 (45.3)	26 (68.4)	
Grade I		14 (21.9)	9 (23.7)	
Grade II		21 (32.8)	3 (7.9)	
MPR status	102			0.044
MPR–		57 (89.1)	28 (73.7)	
MPR+		7 (10.9)	10 (26.3)	
VT (%)	102	52 (28-67)	28 (8-46)	< 0.001

Values are presented as median (IQR) or number (%). ADC, adenocarcinoma; CCRT, concurrent chemoradiation therapy; IQR, interquartile range; MPR, major pathologic response; SqCC, squamous cell carcinoma; STAS, tumor spread through air space; VT, viable tumor. ^{a)}Wilcoxon rank-sum test; Pearson's Chi-squared test; Fisher's exact test, ^{b)}Tumor size reduction was assessed based on the tumor longitudinal diameter confirmed by computed tomography (CT) at two different points of time; one was by the time of initial diagnosis, and the other was by the last CT before surgery after neoadjuvant therapy was completed, ^{c)}Others include one patient treated with doxorubicin/cisplatin, and one patient with etoposide/cisplatin, ^{d)}STAS was classified into two groups by its distance from the main tumor. STAS I: < 2,500 μ m [one field of $\times 10$ objective lens] from the edge of main tumor and STAS II: \geq 2,500 μ m from the edge of main tumor.